Q32 Bio (QTTB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Election of Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to serve until the 2029 Annual Meeting or until a successor is elected or qualified.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve the compensation of named executive officers.
Provision to transact any other business properly brought before the Annual Meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Directors up for election are nominated for a term ending at the 2029 Annual Meeting.
Executive compensation and say-on-pay
Advisory, non-binding vote on the compensation of named executive officers is included as a proposal.
Latest events from Q32 Bio
- Q1 2026 net loss narrowed to $7.6M; cash runway into 2028 after equity raises and asset sale.QTTB
Q1 20265 May 2026 - Lead asset bempikibart delivers durable AA responses and strong safety, with pivotal data due mid-2026.QTTB
Company presentation5 May 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with strong governance.QTTB
Proxy filing30 Apr 2026 - Lead asset bempikibart targets unmet needs in alopecia areata, with pivotal data due mid-year.QTTB
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Bempikibart delivers durable, safe hair regrowth in AA, with pivotal data expected mid-2026.QTTB
Company presentation10 Mar 2026 - Q4 2025 net income surged on asset sales, with cash runway secured into late 2027.QTTB
Q4 202510 Mar 2026 - Bempikibart shows promise as a safer, durable biologic for alopecia areata, with key data due midyear.QTTB
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - Durable hair regrowth in AA positions bempikibart as a potential first-line biologic therapy.QTTB
TD Cowen 45th Annual Healthcare Conference3 Feb 2026 - Phase II readouts for benpicobart in atopic dermatitis and alopecia are expected in Q4 2024.QTTB
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026